NCT05831631 Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
| NCT ID | NCT05831631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pietro Mortini, MD, Prof. |
| Condition | Brain Tumor, Primary |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-08-01 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-08-01 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.
Eligibility Criteria
Inclusion criteria: * Adult patients (≥18 years) * Able to express informed consent * With primary or secondary malignant brain tumor * Requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery) Exclusion Criteria: * Patients who do not meet inclusion criteria.
Contact & Investigator
Pietro Mortini, MD, Prof.
STUDY DIRECTOR
IRCCS San Raffaele Scientific Institute
Frequently Asked Questions
Who can join the NCT05831631 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Tumor, Primary. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05831631 currently recruiting?
Yes, NCT05831631 is actively recruiting participants. Contact the research team at sincinelli.laura@hsr.it for enrollment information.
Where is the NCT05831631 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05831631 clinical trial?
NCT05831631 is sponsored by Pietro Mortini, MD, Prof.. The principal investigator is Pietro Mortini, MD, Prof. at IRCCS San Raffaele Scientific Institute. The trial plans to enroll 200 participants.